5620 results about "Assay" patented technology

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Provided herein are methods, compositions, and kits for the spatial detection of analytes using ligation-based capture assays.

Provided herein are methods, compositions, and kits for reducing mislocalization of analytes hybridized to an array on a second substrate from a biological sample mounted on a first substrate in the context of an array-based spatial assay. The methods, compositions, and kits include application of a gel composition to the first substrate and / or the second substrate to reduce mislocalization of analytes.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure provides methods and assay systems for use in spatially encoded biological assays, including assays to determine a spatial pattern of abundance, expression, and / or activity of one or more biological targets across multiple sites in a sample. In particular, the biological targets comprise proteins, and the methods and assay systems do not depend on imaging techniques for the spatial information of the targets. The present disclosure provides methods and assay systems capable of high levels of multiplexing where reagents are provided to a biological sample in order to address tag the sites to which reagents are delivered; instrumentation capable of controlled delivery of reagents; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

A system including a processor and memory coupled to the processor. The system also includes a lateral flow assay (“LFA”) strip reader coupled to the processor for transmitting an LFA strip image to the processor. The processor initiates a sterilization process when the LFA strip image includes a visual feature indicating a sterilization trigger.

Nucleic acid hybridization buffer formulations and uses thereof are described that yield improvements in hybridization specificity, rate, and efficiency. The buffer formulation composition includes a target nucleic acid; at least one polar, aprotic, organic solvent, and a pH buffer system, wherein the target nucleic acid is attached to the surface via hybridization to a surface bound nucleic acid tethered to the surface, and wherein the hybridization of the target nucleic acid and surface bound nucleic acid has a high stringency and annealing rate.

The invention belongs to the technical field of water quality remote sensing monitoring, and particularly relates to a sky-ground remote sensing integrated lake and reservoir water quality parameter quantitative inversion method. Qualitative inversion is carried out on water quality parameters through medium-high resolution satellite remote sensing images, and ground sampling points are reasonably arranged. And carrying out ground and air collaborative operation, including on-site water body sampling and unmanned aerial vehicle flight, so as to ensure the consistency of sampled water quality parameters and unmanned aerial vehicle image spectral characteristics. The sampling point water body sample is sent to a laboratory to be tested, and measured data are obtained. An unmanned aerial vehicle image is subjected to preprocessing including splicing and radiation correction, and a reflectivity image map is obtained. Water vector data are extracted by using an unmanned aerial vehicle image, a remote sensing quantitative inversion model of water quality parameters is established, and the model is analyzed and optimized through an optimal wave band combination. And in combination with the unmanned aerial vehicle image, the inversion model and the water body vector data, obtaining a water quality parameter quantitative inversion result and spatial distribution characteristics in the lake and reservoir range. The method can improve ground sampling rationality and time coordination of lake and reservoir water quality monitoring, and supports long-term high-precision dynamic monitoring.

The invention belongs to the field of molecular biology and immunology, and particularly relates to an anti-CD3 nano antibody capable of activating the activity of T cells as well as a preparation method and application of the anti-CD3 nano antibody. The invention provides a preparation method of the anti-CD3 nano antibody. The preparation method comprises the following steps: constructing a CD3 plasmid and an overexpression cell line, and immunizing alpaca to obtain peripheral blood mononuclear cells (PBMC) of the alpaca; extracting RNA (Ribonucleic Acid) and carrying out reverse transcription to obtain cDNA; carrying out PCR amplification on the antibody gene segment and cloning the antibody gene segment to a phage display vector; and electrically transforming the vector into SS320 competent cells to obtain the nano antibody library. After two rounds of panning, detecting and screening an antibody clone capable of being combined with the CD3 protein through ELISA (Enzyme-Linked Immunosorbent Assay); an antibody sequence is selected through sequencing, and an antibody protein is expressed by using a mammalian cell high-throughput expression system; and then detecting and screening the antibody which is only specifically combined with the CD3. The method disclosed by the invention is simple, convenient and rapid to operate, and can be used for preparing active antibodies for treating potential tumors and proliferative diseases.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure is drawn to methods of utilizing nucleic acid barcodes and corresponding amplifying sites in cells in which the barcodes naturally occur. These barcodes and amplifying sites are reconfigured into a single nucleic acid cassette that provides for ease of use in tagging particular species, strains, or variants of cells, each with a different barcode. These barcodes can be used to track the colonization capabilities of the barcoded cells. The present disclosure further provides for assays that utilize natural barcodes to measure relative microbial colonization ability of a plant root system.

Methods and Kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and / or nucleic acid recording of a molecular interaction and / or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Assays that do not require the cyclic transfer of information between a coding tag and a recording tag are also disclosed, including single cycle assays.

The present disclosure provides, among other things, single sample multi-attribute methods of simultaneously identifying and / or quantifying RNA capping and tailing modifications. The present disclosure provides, among other things, oligonucleotides comprising RNA and DNA bases that are complementary to the 5' and 3' ends of RNA. Provided herein is a method of manufacturing RNA for therapeutic use having a quantified percentage of capped and untailed mRNA, and a specified poly A tail length and polydispersity. Also provided herein is a quality control assay for a manufacturing lot.

The present disclosure relates to methods, compositions and systems for haplotype phasing and copy number variation assays. Included within this disclosure are methods and systems for combining the barcode comprising beads with samples in multiple separate partitions, as well as methods of processing, sequencing and analyzing barcoded samples.

The invention discloses monoclonal antibodies NP5 and NP8 for resisting influenza A virus NP protein and application of the monoclonal antibodies NP5 and NP8, and belongs to the technical field of monoclonal antibodies. According to the invention, 19 influenza A virus NP protein monoclonal antibodies are prepared, and the monoclonal antibodies NP5 and NP8 are obtained by screening through ELISA (enzyme-linked immuno sorbent assay) detection and sequencing analysis. The NP5 comprises a light chain CDR2 of which the amino acid sequence is RTS, light chains CDR1 and CDR3 of which the amino acid sequences are shown as SEQ ID NO.3-4, and heavy chains CDR1-3 of which the amino acid sequences are shown as SEQ ID NO.7-9; the NP8 comprises a light chain CDR2 of which the amino acid sequence is LVS, light chains CDR1 and CDR3 of which the amino acid sequences are as shown in SEQ ID NO.12 to SEQ ID NO.13, and heavy chains CDR1-3 of which the amino acid sequences are as shown in SEQ ID NO.16 to SEQ ID NO.18. The invention lays a foundation for preparing an influenza A virus detection kit.

Described herein are multi-well separation devices configured to allow a composition comprising a target agent to be separated into multiple wells, subdivided, recombined into a single well, and / or re-separated into the same or a different configuration of wells. Also described herein are reagent loading devices configured to simultaneously deliver one or more test agents to a plurality of volumes without having to individually deliver the test agents. Together, these devices allow high throughput parallel processes without repetitive pipetting or liquid handling robotics, though they may also be used separately. Also described herein are kits and systems for chemical or biological assays, as well as methods for using the multi-well separation devices and reagent loading devices described herein.

The invention relates to the technical field of biology, in particular to a preparation method and application of an anti-human MUC1 antibody, and provides a recombination system which utilizes an in-vitro B cell culture technology, uses ELISA (enzyme-linked immunosorbent assay) to detect the expression condition of the antibody, performs flow detection on the binding capacity level with cells and performs antibody expression and assembly through an expression vector. The monoclonal antibody with high specificity and strong affinity is screened out, and the immunogenicity is reduced on the basis that the high affinity combined with the antigen is reserved through humanized transformation, so that the monoclonal antibody is favorably applied to immunotherapy of a human body; the anti-human MUC1 antibody prepared by the invention plays an important role in immunotherapy of tumors, and solves the technical problems of insufficient specificity and lower affinity of the MUC1 antibody in the prior art.

The invention discloses a camel source single-domain antibody GH12 for recognizing a conformation B cell epitope in clostridium difficile glutamate dehydrogenase and application of the camel source single-domain antibody GH12. The nucleotide sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 2. The camel source single-domain antibody GH12 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody GH12 can be used for detecting recombinant expressed CD-GDH and endogenous CD-GDH by enzyme-linked immunosorbent assay (ELISA), protein dot blot hybridization (DB) and other methods.

Method and systems for quantifying analytes in biological samples include a lateral flow assay (LFA). Integrated LFA analyte measuring devices include a first sensor that generates a signal relative to the concentration of a measured analyte. The LFA device may also include one or multiple additional sensors for auxiliary measures to assist in correcting, adjusting, or interpreting the output of the first sensor. The LFA device can cooperate with a remote database for data storage, analysis, and access.

The present disclosure relates to methods, compositions and systems for haplotype phasing and copy number variation assays. Included within this disclosure are methods and systems for combining the barcode comprising beads with samples in multiple separate partitions, as well as methods of processing, sequencing and analyzing barcoded samples.

The invention relates to the technical field of chemical production process control, and particularly discloses a production process export quality prediction method based on performance-driven knowledge distillation, which comprises the following steps: step 1, acquiring observable process data of an industrial production process and test data of export quality indexes, and forming a data set; 2, cleaning and standardizing the data set, and randomly dividing the data set into a training set, a verification set and a test set according to a certain proportion; 3, building a basic quality predictor, and embedding an LSTM module into the basic quality predictor through a twinning neural network framework; 4, training a plurality of basic twin LSTM quality predictors to obtain a teacher model; step 5, training student models with the same structure by taking performance as drive and combining knowledge distillation and supervised learning; and step 6, inputting process data of the test sample, and obtaining an output predicted value, so as to improve the accuracy of the soft measurement of the production quality index in the industrial process on the basis of ensuring the stability of the model.

The invention discloses a monoclonal antibody BY017 combined with African swine fever virus P30 protein and application of the monoclonal antibody BY017. The invention provides an IgG antibody which is composed of a light chain and a heavy chain. CDR1, CDR2 and CDR3 in the heavy chain variable region are sequentially shown as the 47 to 54 , the 72 to 79 and the 118 to 126 in SEQ ID NO: 1; cDR1, CDR2 and CDR3 in a light chain variable region are sequentially as shown in the 49 to 60 , the 78 to 80 and the 117 to 124 in SEQ ID NO: 3. The invention also protects the application of any one of the IgG antibodies in preparation of products. The product has the functions that the product is used for being combined with an African swine fever virus P30 protein fragment; the antibody is used for binding African swine fever virus P30 protein; the antibody is used for binding African swine fever virus. The IgG antibody provided by the invention can be used for multiple purposes of western blot, immunohistochemistry, flow cytometry, ELISA (Enzyme-Linked Immunosorbent Assay) and the like, and can be used as an important tool for ASFV detection and structural analysis of P30 protein of ASFV detection.